Trending...
- Psychologist-Turned-Hermeticist Releases Modern Guide to the Seven Hermetic Principles
- Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
- Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
BURLINGAME, Calif.--(BUSINESS WIRE)--Genesis Therapeutics, a company pioneering AI technologies to create medicines for patients with severe and unmet medical needs, today announced the appointment of Will McCarthy as chief business officer.
"We are excited to welcome Will to our rapidly growing team." said Evan N. Feinberg, Ph.D., Genesis Therapeutics' CEO and co-founder. "He is an industry leader with a track record of success driving strategic partnerships, commercial planning and operations at innovative biotech companies."
Previously Mr. McCarthy was chief business officer at Generation Bio, a gene therapy company, and was part of the team that took the company public in 2020. Before that he was chief business officer at Ignyta, a company focused on genetically defined cancers, and held that role until the acquisition by Roche in 2018. Earlier in his career he was vice president of corporate development at Foundation Medicine and held business development and commercial roles at Halozyme Therapeutics, Biogen Idec and Neurocrine Biosciences. He began his career as a strategy consultant at IMS health and Deloitte Consulting and obtained a Master of Business Administration from London Business School and a Bachelor of Arts degree in economics from the University of Exeter.
More on The Californer
Mr. McCarthy joins Genesis Therapeutics at the same time as the company was selected for the Forbes AI 50 Companies to Watch list for the second consecutive year.
"Genesis Therapeutics has already accomplished a great deal – internally and in terms of partnerships – in a very short amount of time," commented Mr. McCarthy. "I was drawn to Genesis because of its unprecedented technology and the unique potential of its AI platform, especially in the hands of a world-class drug discovery team, to create transformative medicines for patients."
Genesis Therapeutics completed a $52 Million Series A round of financing in December 2020 and is progressing both an internal drug pipeline, as well as select external partnerships, to create transformative therapies for patients. The company announced a multi-target partnership with Genentech in October 2020.
More on The Californer
About the Genesis Therapeutics Molecular AI Platform
Genesis Therapeutics has developed Dynamic PotentialNet and other novel neural network algorithms that examine drug-target complexes as flexible, spatial graphs -- enabling superior prediction of potency and selectivity of drug candidates. The company's technology offers significant advantages in addressing novel, previously undruggable targets in addition to well-characterized therapeutic targets. Genesis Therapeutics' AI engineering team partners closely with its medicinal chemists to execute and continuously strengthen an innovative process for drug discovery and early development. Genesis Therapeutics' robust infrastructure scales the company's AI platform on the Cloud, enabling the company to combine its proprietary Molecular Generation Engine with its field-leading molecular property predictors to search immense swaths of chemical space, approaching drug discovery as a multiparameter optimization problem.
About Genesis Therapeutics
Genesis Therapeutics is a biotechnology company that invents and deploys breakthrough AI techniques to discover and develop drugs both internally as well as in select partnerships. Genesis Therapeutics is unique in its groundbreaking deep learning technology, its synergy of machine learning with biophysical simulation and its pairing of AI with extensive biotech/pharma expertise. Genesis Therapeutics was founded in 2019 with origins in AI research at Stanford University by its co-founder and CEO, Evan Feinberg, Ph.D. The company is headquartered in Burlingame, CA. To learn more, visit genesistherapeutics.ai.
"We are excited to welcome Will to our rapidly growing team." said Evan N. Feinberg, Ph.D., Genesis Therapeutics' CEO and co-founder. "He is an industry leader with a track record of success driving strategic partnerships, commercial planning and operations at innovative biotech companies."
Previously Mr. McCarthy was chief business officer at Generation Bio, a gene therapy company, and was part of the team that took the company public in 2020. Before that he was chief business officer at Ignyta, a company focused on genetically defined cancers, and held that role until the acquisition by Roche in 2018. Earlier in his career he was vice president of corporate development at Foundation Medicine and held business development and commercial roles at Halozyme Therapeutics, Biogen Idec and Neurocrine Biosciences. He began his career as a strategy consultant at IMS health and Deloitte Consulting and obtained a Master of Business Administration from London Business School and a Bachelor of Arts degree in economics from the University of Exeter.
More on The Californer
- John Duffy Competes in Mr Muscle Beach
- New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
- Thorn & Bloom Magazine Unveils Groundbreaking Second Edition: "Breaking the Cycle"
- Cheap O SMS Launches Groundbreaking Free SMS API Service
- California: Governor Newsom signs legislation 7.3.25
Mr. McCarthy joins Genesis Therapeutics at the same time as the company was selected for the Forbes AI 50 Companies to Watch list for the second consecutive year.
"Genesis Therapeutics has already accomplished a great deal – internally and in terms of partnerships – in a very short amount of time," commented Mr. McCarthy. "I was drawn to Genesis because of its unprecedented technology and the unique potential of its AI platform, especially in the hands of a world-class drug discovery team, to create transformative medicines for patients."
Genesis Therapeutics completed a $52 Million Series A round of financing in December 2020 and is progressing both an internal drug pipeline, as well as select external partnerships, to create transformative therapies for patients. The company announced a multi-target partnership with Genentech in October 2020.
More on The Californer
- Fireworks, fun, and safety: California preps for the holiday weekend
- BillBoards Inc. Hits the Road with God Bless America Tour and Reality Series Now Streaming on Tubi TV
- Legacy vs. Legacy Gala: Celebrating the Past, Powering the Future of the L.A. Watts Summer Games
- Orion Retreats: Pioneering the Future of Conscious Leadership and Luxury Wellness Tourism
- Cynthia Pinot Among Artists Selected for Renowned London Art Biennale 2025
About the Genesis Therapeutics Molecular AI Platform
Genesis Therapeutics has developed Dynamic PotentialNet and other novel neural network algorithms that examine drug-target complexes as flexible, spatial graphs -- enabling superior prediction of potency and selectivity of drug candidates. The company's technology offers significant advantages in addressing novel, previously undruggable targets in addition to well-characterized therapeutic targets. Genesis Therapeutics' AI engineering team partners closely with its medicinal chemists to execute and continuously strengthen an innovative process for drug discovery and early development. Genesis Therapeutics' robust infrastructure scales the company's AI platform on the Cloud, enabling the company to combine its proprietary Molecular Generation Engine with its field-leading molecular property predictors to search immense swaths of chemical space, approaching drug discovery as a multiparameter optimization problem.
About Genesis Therapeutics
Genesis Therapeutics is a biotechnology company that invents and deploys breakthrough AI techniques to discover and develop drugs both internally as well as in select partnerships. Genesis Therapeutics is unique in its groundbreaking deep learning technology, its synergy of machine learning with biophysical simulation and its pairing of AI with extensive biotech/pharma expertise. Genesis Therapeutics was founded in 2019 with origins in AI research at Stanford University by its co-founder and CEO, Evan Feinberg, Ph.D. The company is headquartered in Burlingame, CA. To learn more, visit genesistherapeutics.ai.
Filed Under: Business
0 Comments
Latest on The Californer
- DetailAxis Unveils it's 'Business Engine': Powerful AI Systems for Auto Appearance Pros
- California: Governor Newsom announces appointments 7.2.25
- The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side
- Digital Watchdog Launches New myDW Cloud Services
- Governor Newsom honors fallen California Highway Patrol Officer Miguel Cano
- Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter
- Drone Light Shows Emerge as the New Standard in Live Event Entertainment
- Lore Link is Here to Help Organize Your Game
- Governor Newsom marks historic expansion of California's Film and Television Tax Credit Program, announces 16 new projects to film in the Golden State
- Talar Guedikian Named Winner of 2025 AAJ Paralegal of the Year Award, Sponsored by Advocate Capital
- Chappaqua's Annual Townwide Summer Sale – Unbeatable Savings at Your Favorite Local Boutiques!
- Skyline Partners with ZenSpace to Offer Private Meeting Pods for Trade Show Exhibitors
- California: Did gas prices go up by 65 cents at the pump? No.
- Snell & Wilmer Welcomes Associate Victoria Cendejas to the Orange County Office
- Crime in California drops again — state records second-lowest homicide rate since 1966
- FireAid Donates $75,000 To California Strong To Distribute To Palisades and Eaton Fire Victims
- Celebrate Safely: 4th of July BBQ & Celebration Essentials from Mercury Insurance
- AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
- Construcción del Corredor Norte–Sur (NSC) de Singapur
- New Report: Slip and Fall Accidents Rank as the Leading Cause of Construction Site Fatalities